154 related articles for article (PubMed ID: 33787834)
1. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial.
Mayer K; Hein-Rothweiler R; Schüpke S; Janisch M; Bernlochner I; Ndrepepa G; Sibbing D; Gori T; Borst O; Holdenrieder S; Kupka D; Petzold T; Bradaric C; Okrojek R; Leistner DM; Trippel TD; Münzel T; Landmesser U; Pieske B; Zeiher AM; Gawaz MP; Hapfelmeier A; Laugwitz KL; Schunkert H; Kastrati A; Massberg S
JAMA Cardiol; 2021 Jul; 6(7):753-761. PubMed ID: 33787834
[TBL] [Abstract][Full Text] [Related]
2. Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial.
Schüpke S; Hein-Rothweiler R; Mayer K; Janisch M; Sibbing D; Ndrepepa G; Hilz R; Laugwitz KL; Bernlochner I; Gschwendtner S; Kupka D; Gori T; Zeiher AM; Schunkert H; Massberg S; Kastrati A;
Thromb Haemost; 2019 Sep; 119(9):1539-1545. PubMed ID: 31226721
[TBL] [Abstract][Full Text] [Related]
3. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial.
Uphaus T; Richards T; Weimar C; Neugebauer H; Poli S; Weissenborn K; Imray C; Michalski D; Rashid H; Loftus I; Rummey C; Ritter M; Hauser TK; Münch G; Gröschel K; Poppert H
Stroke; 2022 Sep; 53(9):2718-2729. PubMed ID: 35695006
[TBL] [Abstract][Full Text] [Related]
4. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
5. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.
Tcheng JE; Harrington RA; Kottke-Marchant K; Kleiman NS; Ellis SG; Kereiakes DJ; Mick MJ; Navetta FI; Smith JE; Worley SJ
Circulation; 1995 Apr; 91(8):2151-7. PubMed ID: 7697843
[TBL] [Abstract][Full Text] [Related]
9. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
[TBL] [Abstract][Full Text] [Related]
10. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
11. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
Circulation; 1997 Sep; 96(5):1445-53. PubMed ID: 9315530
[TBL] [Abstract][Full Text] [Related]
12. The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.
Goebel S; Li Z; Vogelmann J; Holthoff HP; Degen H; Hermann DM; Gawaz M; Ungerer M; Münch G
PLoS One; 2013; 8(7):e66960. PubMed ID: 23935828
[TBL] [Abstract][Full Text] [Related]
13. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial.
Gröschel K; Uphaus T; Loftus I; Poppert H; Diener HC; Zobel J; Münch G
TH Open; 2020 Oct; 4(4):e393-e399. PubMed ID: 33274312
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
[TBL] [Abstract][Full Text] [Related]
15. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Chichareon P; Modolo R; Kerkmeijer L; Tomaniak M; Kogame N; Takahashi K; Chang CC; Komiyama H; Moccetti T; Talwar S; Colombo A; Maillard L; Barlis P; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Valgimigli M; Windecker S; Onuma Y; Mehran R; Serruys PW
JAMA Cardiol; 2020 Jan; 5(1):21-29. PubMed ID: 31693078
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
[TBL] [Abstract][Full Text] [Related]
17. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans.
Ungerer M; Rosport K; Bültmann A; Piechatzek R; Uhland K; Schlieper P; Gawaz M; Münch G
Circulation; 2011 May; 123(17):1891-9. PubMed ID: 21502572
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
[TBL] [Abstract][Full Text] [Related]
19. Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial.
Mehran R; Chandrasekhar J; Urban P; Lang IM; Windhoevel U; Spaulding C; Copt S; Stoll HP; Morice MC;
JAMA Cardiol; 2020 Aug; 5(8):939-947. PubMed ID: 32432718
[TBL] [Abstract][Full Text] [Related]
20. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
